MagArray

Applied Microarrays (“AMI”) was founded in 2006 by CEO Alastair Malcolm, with the business model of manufacturing Point-of-Care and High Throughput DNA and protein arrays whose custom bio-content is developed by AMI’s customers. The array manufacturing equipment from GE has unique features enabling quality, accuracy and repeatability not available in tools sold on the general market. In October 2021 AMI was acquired by SCHOTT MINIFAB, a world leading microfluidic diagnostics and lifescience company. Combined, AMI and SCHOTT MINIFAB have a team of over 300 specialists with manufacturing sites in Europe, Australia and USA. Accordingly we treat our customer engagements with quality systems that will enable their products to be accepted successfully in regulated markets.

Arrayit customers include the brightest minds in university laboratories, government laboratories, biotechnology companies, life sciences companies, clinical laboratories, pharmaceutical companies and hospitals worldwide. Arrayit microarray technology empowers scientists with the tools required to make important discoveries and change the world. Arrayit microarray technology products and services are featured in more than 6,000 peer-reviewed scientific publications, for the ultimate in scientific credibility. Arrayit microarray technology miniaturizes traditional tests by 100-fold or more, which reduces manufacturing and personnel costs, increases testing throughput and packs tremendous scientific content into each research test. Arrayit microarray technology affords life sciences researchers with the tools required to identify these markers, leading potentially to transformative healthcare advances. Arrayit offers a full suite of microarray-based products and services to empower researchers with the tools required to make next generation discoveries for human kind. Arrayit sets the standard in the microarray industry with ArrayIt® Brand DNA Microarrays. Arrayit sets the standard for the microarray industry with ArrayIt® brand Purification Products.

MagnaBioSciences, LLC (MBS) is a privately held company founded in 2000 and headquartered in San Diego, California. Our quality policy: We are committed to meeting customer requirements by consistently producing safe and effective products, maintaining the effectiveness of our Quality Management System and complying with all applicable laws and regulations. MBS is the proprietor of Magnetic Immuno-Chromatographic Test® (MICT) technology. This technology merges the physics of magnetics with nano biotechnology to provide assays of broad applications in numerous areas. MBS developed the MICT system to provide for rapid and accurate immunoassays of a variety of biochemical and environmental samples, based on the well-known lateral flow format. MICT tests are read magnetically, offering the advantages of a quantitative result and greatly improved sensitivity. In addition to the MICT instruments, we offer assay development and manufacturing services with a commitment to deliver high quality and innovative products to our customers.

Microarray Ltd is a UK-based specialist wound healing company. Founded in 2000 as a spin-out from Manchester Universities, the company is now privately owned and has office and laboratory facilities at Colworth Science Park and Cranfield University. The company has wide ranging expertise in the fields of wound dressing product development, marketing and sales; electrochemistry and diagnostic sensor technologies; biochemistry, oxygen and iodine chemistry; enzymology, immunology and inflammation. Current research and development activities are concentrated on innovative, electrochemically-active wound dressings for the treatment of chronic wounds and on wound care diagnostics. Microarray owns and continues to develop new intellectual property in its specialist fields. It works independently and with expert academic and industrial partners.

INTER-ARRAY combines bioanalytics with state-of-the-art microtechnologies, especially in the field of high precision microdispensing. INTER-ARRAY is partner of companies and institutions in the fields of medicine and medical technology, diagnostics, environmental analysis and pharmaceutical development. INTER-ARRAY is part of fzmb GmbH, Research Center for Medical Technology and Biotechnology (Germany), which has extensive experience in immunochemistry, biomedicine and bioanalytics. INTER-ARRAY supports its partners in all microarray development stages, from feasibility study, optimization, verification and validation to pilot production. INTER-ARRAY offers solutions for multiparameter assay development and validation for any application in human and veterinary diagnostics and life sciences. INTER-ARRAY is a full service provider in the life science sector with its protein and antibody, molecular, microbiology, bioconjugation and surface technology labs. INTER-ARRAY Genotyping Kits allow DNA-based detection of antibiotic resistance genes, virulence genes and pathogenicity markers of different multi-resistant pathogens by simple and quick assignment of unknown isolates to known strains within hours. Founded in 1994 by biotechnologists, engineers and physicians, the ISO-certified company today develops and manufactures innovative, high-quality diagnostic products for laboratory and point-of-care applications.

QDTI's all-magnetic approach solves the key limitations with current state-of-the-art optical detection-based technologies for biomarkers, including: long time to results; cumbersome, extensive sample washing; and, significant environmental, resource and financial costs. The QDTI imaging platform – using magnetic tags – enables an inexpensive, more reliable, more flexible way to achieve a high-performance biomarker detection. The QDTI magnetic detection approach improves identification of multiple types of biomarkers – proteins, nucleic acids, cells – and will impact all phases of biomedical research and patient care. The QDTI system uses quantum mechanics to enable ultrasensitive detection of biomarkers. The QDTI diagnostic protocol requires only 5µL of sample to perform the assay – a critical benefit when sample availability is limited. The QDTI magnetic-based assay requires minimal sample processing. The QDTI approach requires 90% less hands-on time. QDTI is building a flexible system from the start.